sudhl5 Search Results


sudhl5 cell line  (ATCC)
95
ATCC sudhl5 cell line
Selecting multiple points from the volcano plot renders a heatmap of these features, allowing for inspection of within-group variance and comparison of differential abundance across additional groups in the data. Upregulated phosphosites, outlined by a box in the volcano plot, from the <t>SUDHL5</t> iCCK1 – SUDHL5 DMSO comparison were selected for plotting a heatmap. The heatmap displays the scaled normalized values. The phosphosite effects were strongly similar in SUDHL5_iCCK2. These phosphosites tend to be upregulated in VAL following iCCK treatment, but are not significant and are inhibitor-specific.
Sudhl5 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl5 cell line/product/ATCC
Average 95 stars, based on 1 article reviews
sudhl5 cell line - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
amaxatm cell line nucleofectortm kit v  (Lonza)
90
Lonza amaxatm cell line nucleofectortm kit v
Selecting multiple points from the volcano plot renders a heatmap of these features, allowing for inspection of within-group variance and comparison of differential abundance across additional groups in the data. Upregulated phosphosites, outlined by a box in the volcano plot, from the <t>SUDHL5</t> iCCK1 – SUDHL5 DMSO comparison were selected for plotting a heatmap. The heatmap displays the scaled normalized values. The phosphosite effects were strongly similar in SUDHL5_iCCK2. These phosphosites tend to be upregulated in VAL following iCCK treatment, but are not significant and are inhibitor-specific.
Amaxatm Cell Line Nucleofectortm Kit V, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amaxatm cell line nucleofectortm kit v/product/Lonza
Average 90 stars, based on 1 article reviews
amaxatm cell line nucleofectortm kit v - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
sudhl5  (DSMZ)
93
DSMZ sudhl5
Selecting multiple points from the volcano plot renders a heatmap of these features, allowing for inspection of within-group variance and comparison of differential abundance across additional groups in the data. Upregulated phosphosites, outlined by a box in the volcano plot, from the <t>SUDHL5</t> iCCK1 – SUDHL5 DMSO comparison were selected for plotting a heatmap. The heatmap displays the scaled normalized values. The phosphosite effects were strongly similar in SUDHL5_iCCK2. These phosphosites tend to be upregulated in VAL following iCCK treatment, but are not significant and are inhibitor-specific.
Sudhl5, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl5/product/DSMZ
Average 93 stars, based on 1 article reviews
sudhl5 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
ros 50  (DSMZ)
90
DSMZ ros 50
Selecting multiple points from the volcano plot renders a heatmap of these features, allowing for inspection of within-group variance and comparison of differential abundance across additional groups in the data. Upregulated phosphosites, outlined by a box in the volcano plot, from the <t>SUDHL5</t> iCCK1 – SUDHL5 DMSO comparison were selected for plotting a heatmap. The heatmap displays the scaled normalized values. The phosphosite effects were strongly similar in SUDHL5_iCCK2. These phosphosites tend to be upregulated in VAL following iCCK treatment, but are not significant and are inhibitor-specific.
Ros 50, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ros 50/product/DSMZ
Average 90 stars, based on 1 article reviews
ros 50 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
diffuse large b cell lymphoma  (DSMZ)
94
DSMZ diffuse large b cell lymphoma
Selecting multiple points from the volcano plot renders a heatmap of these features, allowing for inspection of within-group variance and comparison of differential abundance across additional groups in the data. Upregulated phosphosites, outlined by a box in the volcano plot, from the <t>SUDHL5</t> iCCK1 – SUDHL5 DMSO comparison were selected for plotting a heatmap. The heatmap displays the scaled normalized values. The phosphosite effects were strongly similar in SUDHL5_iCCK2. These phosphosites tend to be upregulated in VAL following iCCK treatment, but are not significant and are inhibitor-specific.
Diffuse Large B Cell Lymphoma, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/diffuse large b cell lymphoma/product/DSMZ
Average 94 stars, based on 1 article reviews
diffuse large b cell lymphoma - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
dlbcl cell lines  (DSMZ)
95
DSMZ dlbcl cell lines
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Dlbcl Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlbcl cell lines/product/DSMZ
Average 95 stars, based on 1 article reviews
dlbcl cell lines - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
indications cell line source indication sudhl5 dsmz b cell lymphoma gc dlbcl  (DSMZ)
95
DSMZ indications cell line source indication sudhl5 dsmz b cell lymphoma gc dlbcl
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Indications Cell Line Source Indication Sudhl5 Dsmz B Cell Lymphoma Gc Dlbcl, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/indications cell line source indication sudhl5 dsmz b cell lymphoma gc dlbcl/product/DSMZ
Average 95 stars, based on 1 article reviews
indications cell line source indication sudhl5 dsmz b cell lymphoma gc dlbcl - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
dlbcl cell lines  (ATCC)
96
ATCC dlbcl cell lines
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Dlbcl Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dlbcl cell lines/product/ATCC
Average 96 stars, based on 1 article reviews
dlbcl cell lines - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
sudhl4  (CEM Corporation)
90
CEM Corporation sudhl4
Figure 2. Iron chelators and ironomycin inhibit <t>DLBCL</t> <t>cell</t> growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.
Sudhl4, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sudhl4/product/CEM Corporation
Average 90 stars, based on 1 article reviews
sudhl4 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Selecting multiple points from the volcano plot renders a heatmap of these features, allowing for inspection of within-group variance and comparison of differential abundance across additional groups in the data. Upregulated phosphosites, outlined by a box in the volcano plot, from the SUDHL5 iCCK1 – SUDHL5 DMSO comparison were selected for plotting a heatmap. The heatmap displays the scaled normalized values. The phosphosite effects were strongly similar in SUDHL5_iCCK2. These phosphosites tend to be upregulated in VAL following iCCK treatment, but are not significant and are inhibitor-specific.

Journal: Molecular omics

Article Title: ProteoViz: A tool for the analysis and interactive visualization of phosphoproteomics data

doi: 10.1039/c9mo00149b

Figure Lengend Snippet: Selecting multiple points from the volcano plot renders a heatmap of these features, allowing for inspection of within-group variance and comparison of differential abundance across additional groups in the data. Upregulated phosphosites, outlined by a box in the volcano plot, from the SUDHL5 iCCK1 – SUDHL5 DMSO comparison were selected for plotting a heatmap. The heatmap displays the scaled normalized values. The phosphosite effects were strongly similar in SUDHL5_iCCK2. These phosphosites tend to be upregulated in VAL following iCCK treatment, but are not significant and are inhibitor-specific.

Article Snippet: The VAL cell line was previously obtained from Dr. Staudt (NCI) and the SUDHL5 cell line was purchased from the American Type Culture Collection (CRL-2958).

Techniques:

Figure 2. Iron chelators and ironomycin inhibit DLBCL cell growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 2. Iron chelators and ironomycin inhibit DLBCL cell growth and decrease the LIP. A–C, DLBCL cells were incubated with different concentrations of iron chelators or vehicle for 96 hours. IC50 was calculated with concentration–response curve after treatment with deferoxamine (A), deferasirox (B), and ironomycin (C). D, Cell viability was examined using quantification of ATP assay. Data are expressed as mean percentage SEM of at least three independent experiments performed in six times. Balb/c mice were inoculated with murine A20 lymphoma cells and when tumor was palpable, the mice were treated with ironomycin (3 mg/kg i.p.). Mice were sacrificed when tumor volume reached 1,500 mm3. Evaluation of the tumor volume of vehicle (n ¼ 10) and ironomycin-treated mice (n ¼ 10). , P < 0.05 using Mann– Whitney test. E, Effect of Ironomycin on LIP was measured by dequenching of Calcein. Cells were loaded with 0.25 mmol/L Calcein-AM for 15 min, washed, and incubated for 1 hour with or without 100 mmol/L deferasirox or 10 mmol/L ironomycin. In this experiment, following treatment, cells were washed and their fluorescence was measured by flow cytometry. The difference in the mean fluorescence index between chelator-treated and untreated cells (DF) is presented. The results represent the mean and SD of at least four independent experiments.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Incubation, Concentration Assay, ATP Assay, MANN-WHITNEY, Cytometry

Figure 4. Iron chelators and ironomycin induce ROS production in DLBCL cells. A and B, Effect of deferoxamine, deferasirox, and ironomycin on the ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe for OCI-LY3 (A) and DB cell line (B) at 48 hours. C, Vehicle and GSH treatment (5 and 0.5 mmol/L, respectively, 1 hour) was used as a negative control and oxygen peroxide (10 mmol/L, 1 hour) as a positive control. For the ROS reversion assay, DB cells were treated with 250 nmol/L Ironomycin for 48 hours with or without GSH or Fer-1 or deferoxamine (DFO). ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe. Chaetocin and erastin were used as positive control for GSH and Fer-1 reversion, respectively. Results represent the mean percentage and SD of three independent experiments. , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001; NS, nonsignificant; with paired Student t test.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 4. Iron chelators and ironomycin induce ROS production in DLBCL cells. A and B, Effect of deferoxamine, deferasirox, and ironomycin on the ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe for OCI-LY3 (A) and DB cell line (B) at 48 hours. C, Vehicle and GSH treatment (5 and 0.5 mmol/L, respectively, 1 hour) was used as a negative control and oxygen peroxide (10 mmol/L, 1 hour) as a positive control. For the ROS reversion assay, DB cells were treated with 250 nmol/L Ironomycin for 48 hours with or without GSH or Fer-1 or deferoxamine (DFO). ROS production was analyzed using flow cytometry after oxidation of a CM-H2DFDA probe. Chaetocin and erastin were used as positive control for GSH and Fer-1 reversion, respectively. Results represent the mean percentage and SD of three independent experiments. , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001; NS, nonsignificant; with paired Student t test.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Cytometry, Negative Control, Positive Control

Figure 7. Ironomycin presents a significant toxicity on DLBCL primary cells and potentializes doxorubicin cytotoxicity. A, Primary DLBCL cells were treated with ironomycin and/or doxorubicin and incubated during 96 hours with CD40L. DLBCL cell toxicity was analyzed by flow cytometry. B, Hematopoietic progenitor CFU assay were performed with CD34þ cells from apheresis of 5 donors. Cells were cultured in hydroxyl-methyl-cellulose medium with or without conventional chemotherapy or ironomycin. CFU-C, CFU-E, and CFU-GM were counted after 14-day culture. C, The toxicity of ironomycin alone or in combination with doxorubicin on normal CD3þ cells was assessed by flow cytometry. Results represent the median interquartile ranges of each population (n ¼ 5 patients). Statistical significance was tested using t test of pairs: , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001. D, Primary DLBCL cells of 6 patients and PBMC of a healthy donor were incubated with 5 mmol/L Rho-Nox1 Fe2þ probe. The MFI was assessed by flow cytometry in CD20þ DLBCL cells and CD20 cells (microenvironment cells). E, DB cells were treated with increasing concentrations of ironomycin com- bined with doxorubicin for 96 hours, and cell viability was tested by ATP quantification to obtain the viability matrix. The synergy matrix was calculated as described in Materials and Methods.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 7. Ironomycin presents a significant toxicity on DLBCL primary cells and potentializes doxorubicin cytotoxicity. A, Primary DLBCL cells were treated with ironomycin and/or doxorubicin and incubated during 96 hours with CD40L. DLBCL cell toxicity was analyzed by flow cytometry. B, Hematopoietic progenitor CFU assay were performed with CD34þ cells from apheresis of 5 donors. Cells were cultured in hydroxyl-methyl-cellulose medium with or without conventional chemotherapy or ironomycin. CFU-C, CFU-E, and CFU-GM were counted after 14-day culture. C, The toxicity of ironomycin alone or in combination with doxorubicin on normal CD3þ cells was assessed by flow cytometry. Results represent the median interquartile ranges of each population (n ¼ 5 patients). Statistical significance was tested using t test of pairs: , P < 0.05; , P < 0.01; , P < 0.001; , P < 0.0001. D, Primary DLBCL cells of 6 patients and PBMC of a healthy donor were incubated with 5 mmol/L Rho-Nox1 Fe2þ probe. The MFI was assessed by flow cytometry in CD20þ DLBCL cells and CD20 cells (microenvironment cells). E, DB cells were treated with increasing concentrations of ironomycin com- bined with doxorubicin for 96 hours, and cell viability was tested by ATP quantification to obtain the viability matrix. The synergy matrix was calculated as described in Materials and Methods.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Incubation, Cytometry, Colony-forming Unit Assay, Cell Culture

Figure 8. Ironomycin induces mortality and TFR1 downregulation in primary DLBCL cells. A, Primary DLBCL cells from four patients were cultured with recombinant CD40 L in the presence or absence of ironomycin (500 nmol/L). After 96 hours, cell death of DLBCL cells was monitored by Annexin V/PI staining using flow cytometry. Results represent the mean SD. B, Primary samples of patients with DLBCL were cultured with recombinant CD40 L in presence or absence ironomycin (500 nmol/L). DLBCL cell membrane TFR1 (CD71) expression was assessed by flow cytometry. , P < 0.05; , P < 0.01.

Journal: Cancer research

Article Title: Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.

doi: 10.1158/0008-5472.CAN-21-0218

Figure Lengend Snippet: Figure 8. Ironomycin induces mortality and TFR1 downregulation in primary DLBCL cells. A, Primary DLBCL cells from four patients were cultured with recombinant CD40 L in the presence or absence of ironomycin (500 nmol/L). After 96 hours, cell death of DLBCL cells was monitored by Annexin V/PI staining using flow cytometry. Results represent the mean SD. B, Primary samples of patients with DLBCL were cultured with recombinant CD40 L in presence or absence ironomycin (500 nmol/L). DLBCL cell membrane TFR1 (CD71) expression was assessed by flow cytometry. , P < 0.05; , P < 0.01.

Article Snippet: Human DLBCL cell lines The 16 DLBCL cell lines (U2932, OCI-LY-3, NU-DHL-1, OCI-LY19, DB, SUDHL4, OCILY1, SUDHL5, DOHH2, SUDHL10, HT, RI-1, SU-DHL-6, NUDUL-1, WSU-DLCL-2 and OCI-LY-7) were purchased from theDSMZ (Leibniz-Institut DSMZ -Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

Techniques: Cell Culture, Recombinant, Staining, Cytometry, Membrane, Expressing